Lumida
/SDGR
⌘K
Schrodinger Inc

Schrodinger Inc

SDGR
$19.02USD↑+1.17%+0.22 today

MARKET CAP

1.4B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$19 – $19

52W RANGE

$11
$23

AI Summary

Stalk
Sell NowMedium

SDGR has broken key early-September consolidation support, closing below the rising 9EMA and 20EMA, signaling that buyers can no longer absorb supply and suggesting potential for accelerated downside. Medium-term bias shifts to bearish given the Support Failure pattern, and short-term timing is unfavorable with rejection at EMAs. Execution focuses on sell-side participation into any bounce toward the former support zone near mid-19s, with invalidation on a reclaim and acceptance back above the 9EMA/20EMA area.

  • ↑ACV up 27% YoY to $29.6M; FY ACV guide $218–228M
  • ↑Q2 total revenue $58.9M; drug discovery rev rose to $23M
  • ↓Negative earnings yield and weak profitability factors signal low returns
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Schrödinger, Inc. (NASDAQ: SDGR) operates in the biotechnology space, utilizing physics-based simulations and AI to accelerate drug discovery and improve material design. The company leverages its computational platform and collaborates with prominent players in the industry, demonstrating a strategic advantage in both therapeutics and software across biopharma and materials science sectors. With recent developments such as the formation of Tectora Therapeutics, Schrödinger is positioned to capitalize on growing opportunities within immunology and inflammation therapies, emphasizing its role in the evolving biotech landscape.

Bull says

  • ↑ACV up 27% YoY to $29.6M; FY ACV guide $218–228M
  • ↑Q2 total revenue $58.9M; drug discovery rev rose to $23M
  • ↑BMS Bunsen AI deal drives scalable tech usage in pharma
  • ↑Net income $6M vs. $43M loss a year ago; Opex down 6%
  • ↑Cash $419M boosts liquidity amidst strong growth demand
  • ↑AI-driven Bunsen platform improves chemist productivity

Bear says

  • ↓Negative earnings yield and weak profitability factors signal low returns
  • ↓Hosted licensing transition cuts $2–3M income per 1% shift
  • ↓High stock volatility may deter risk-averse investors
  • ↓Revenue depends on milestone payments subject to timing risks
  • ↓Low quality factors suggest fragile balance sheet despite cash on hand
  • ↓Regulatory and tech disruption risk demands constant R&D updates

Investment themes with SDGR

Health Care Providers↓ -0.37%

UNH · CVS · HCA

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 08-07-2025bullish

Transcript signals

Bull points

  • IND clearance of SGR3515, our V1 NIT1 inhibitor, we now have three clinical stage proprietary programs.
  • We received a milestone upon completing the SOS1 development candidate package,
  • We are on track to have clinical data in late 24 or in 2025.

Bear points

  • During today's call, management will make statements that are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including without limitation, statements related to our outlook for the second quarter and full year 2024, our plans to accelerate the growth of our software business and advance our collaborative and proprietary drug discovery programs, the timing of, initiation of, and readouts from our clinical trials, the clinical potential and properties of our compounds, the use of our cash resources, and our future expenses.
Read full transcript analysis ›